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Abstract Nitricoxide (NO) is animportantmediatorof inflammationin severalpathologicalconditions.Patientswith
lung diseases, like asthma, have higher levels of exhaled NO (eNO) in active disease in comparisonwith healthy volun-
teers. Aspirated colonic gas in patients with ulcerative colitis (UC) showedmore than100 times higher levels of NO in
comparisonwithnormal subjects.Crohn’s disease (CD) and UC are associatedwith a varietyof systemicmanifestations,
althoughlungdiseases as an extra-intestinal expression of inflammatoryboweldisease (IBD) arenotwell investigated.In
some studies, clinical and subclinicalpulmonaryabnormalities are describedin active IBDaswell asinthe stable situation.
The aim of the present study is to evaluate whether eNO is increased in patients with active IBD and to investigate
whether there exists a correlation between (1) the eNOlevels and the disease activity, and (2) the spirometry and the
disease activity in a subgroup of patients. In 31patients with CD (mean age 36.8712.9 years) and 24 patients with UC
(mean age 38.0714.7 years) the Crohn’s Disease Activity Index (CDAI) and Colitis Activity Index (CAI) weremeasured,
respectively.ExhaledNOwasmeasuredwith a chemiluminescence analyzer, according to standardized criteria.In a sub-
group of CDpatients, spirometrywas alsoperformedaccording to standardizedcriteria.ThemeanCDAIinCDpatients
was192.4794.3 and theirmean eNO valuewas13.574.6 ppb.For UCthemean CAIwas 6.274.8 and themean eNO
valuewas15.876.2 ppb.In amatchedcontrolgroup of 27 healthy, non-smoking volunteers (meanage of 33.7713.2 years)
the eNO was10.272.5 ppb (Po 0.05 compared to CD and Po 0.01 compared to UC).There was a disease-activity-
relatedincrease ofthe eNOlevelinpatientswith IBD.ForpatientswithUCthe correlationcoefficient (r¼ 0.63,Po 0.001)
wasmore pronounced than for CD (r¼ 0.39, Po 0.05).In17 patientswith CD, spirometrywas available atthe time ofthe
eNOmeasurement.We found a significant negative correlation between the CDAI and the FEV1and FVC in these pa-
tients (r¼ 0.559, P¼ 0.02 and r¼ 0.634, P¼ 0.006, respectively).We conclude thateNOis increased in active IBD and
correlateswiththe activityofthedisease; furthermore,we foundanegative correlationbetweenspirometryanddisease
activity in patients with CD.These observations strengthen the arguments that IBD is a systemic disease. Further re-
search is needed to try to explain the significance of an increased eNOin IBD.r2002 Publishedby Elsevier Science Ltd
doi:10.1053/rmed.2002.1312, available online at http://www.idealibrary.comon
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Nitric oxide (NO) plays an important role in many phy-
siological and pathological events in the gastrointestinal
tract (1). In patients with active ulcerative colitis (UC)
and Crohn’s disease (CD) for example, indirect citrulline
assays showed increased mucosal synthesis of NO (2,3).
In another study directmeasurement of NOwith a che-Received1October 2001, and accepted in revised form 3 January 2002.
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showed a more than100 times higher NO concentration
in UC patients than in controls (4).This suggests NO as
an important mediator in the in£ammatory process in
patients with in£ammatory bowel disease (IBD).
The extra-intestinal manifestations in IBD (e.g. in the
skin, the joints, the liver and thromboembolic processes)
are rather well known, suggesting that UC and CD are
inducing or are at least part of a systemic disease, of
which the exact pathophysiological mechanisms have to
be elucidated.
Active involvement of the airways in IBD is still a rare
complication. In a recent study asymptomatic alterations
ACTIVITYRELATEDINCREASEOFENO 531in pulmonary function tests (PFT) could be detected in
55%ofpatientswithUC (5).Tzanakis etal. demonstrated
that the function of the small airways and the transfer
factor for CO (Tlco) are a¡ected in patients with IBD
(6). A subclinical in£ammatory reaction is probably the
cause of these abnormalities. Patients with CD were in-
deed demonstrated to have an increased airway eosino-
philia (7). Moreover, an asymptomatic increase of
airways hyperresponsiveness has also been demon-
strated in patients with IBD (8), suggesting persistent
airways in£ammation.
In many but not all in£ammatory lung diseases eleva-
tion of exhaled NO (eNO) has already been demon-
strated, and it has been claimed to be a marker of
airways in£ammation (9). In steroid-naive asthmatics
speci¢cally, a correlation has been found between eNO
and airways hypersensitivity (10) on the onehand and air-
way eosinophilia on the other hand (11).
As a consequence, the aim of the present study
was to investigate whether eNO is increased in
patients with IBD (CD and CU) and if this may re£ect
the in£ammatory bowel disease activity. Furthermore,
we investigated a possible relationship between disease
activity and spirometry in a subgroup of patients
with CD.
PATIENTSANDMETHODS
Patients
Twenty-four patients with UC and 31 patients with CD
were enrolled in the study. Patients were included either
during hospital stay because of an exacerbation of their
IBD or at the outpatient clinic, during follow up. If they
werebeing treatedwith oral or intravenous corticoster-
oids, which are known to decrease the eNO levels, they
were excluded from the study.UCwas diagnosed based
on clinical, radiographic, and pathological features, and
disease activity was calculatedwith the colitis activity in-
dex (CAI). Brie£y, scores were given on the basis of bo-
wel movement frequencies, nocturnal diarrhea,
presence of blood in stools, fecal incontinence, abdom-
inal pain and tenderness and need for antidiarrheal
drugs. Active diseasewas de¢ned as avalue of10 ormore
(12).
The diagnosis of CDwas established according to clin-
ical, radiological, endoscopic, andpathologic criteria, and
disease activity was assessed according to the Crohn’s
disease activity index (CDAI). More than 150 arbitrary
points was de¢ned as active disease (13).
At the time of the study, patients were treated with
either sulfasalazine (systemic or topical), 5-aminosalisylic
acid, azathioprine or a combination of these drugs. Pa-
tients were also asked about their smoking habits.They
ful¢lled all other inclusion criteria such as the absence of
respiratory symptoms and absence of an upper airwaysrespiratory tract infection 6 weeks before the eNO
measurement.
The age-matched control group comprised 27 healthy,
non-smoking volunteers who were recruited from
among the university hospital sta¡.
All subjects gave their informedconsent and the study
was approved by the ethics committee of the university
hospital.
Methods
ExhaledNOwasmeasuredduring a singlebreath exhala-
tion bymeans of an Ecophysics CLD 700 ALMED (Dˇrn-
ten, Switzerland) chemiluminescence analyzer adapted
for online recording. Measurements were made accord-
ing to European Respiratory Society (ERS) guidelines
for the measurement of eNO (14). In brief, subjects per-
formed a slow vital capacity maneuver over a 30-s peri-
od against a ¢xed expiratory resistance with a target
gauge of10^20 cmH2O,whichpreventedauto-inhalation
of NO from the nasopharynx and resulted in a constant
£ow of 200 ml/s. Exhaled air was led via a Hans Rudolph
non-rebreathing valve into a Te£on tubing system con-
nected to the analyzer. Air was continuously sampled
from the exhalation limb of the system at a samplingrate
of 0.7 l/min and a response time of1 s.Results were dis-
played on a chart recorder, and the plateau level was
noted.Three reproducible recordings (i.e.,o15% varia-
tion) were made at 2-min intervals, and the highest of
three readings was used for analysis. All eNO values are
reported in parts per billion (ppb).
The detection limit for NO was 1 ppb, and measure-
ments were made in the same chamber under constant
conditions. Before each measurement, NO zeroing
was performed, usingNO-free air.Two-point calibration
was donewith a certi¢edconcentration ofNO (100 ppb)
balanced with N2, in accordance with the ERS guide-
lines for the measurement of eNO (14). Day-to-day
reproducibility was assessed in preliminary experi-
ments. In a previous paper we demonstrated that
the variability between eNO levels measured at the
same time of dayon three consecutive dayswas less than
10% (10).
Spirometry was performed according to the Ameri-
canThoracic Society guidelines (15).
Statistics
All data are expressed asmean7standard deviation (SD).
Thepaired andunpaired Student’s t-testwasused for sta-
tistical analysis of the data.Correlations weremadewith
Spearmans rank test, linear regression was done with
the least-squaresmethod.
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FIG. 1. Exhaled NO in patients with Crohn’s disease (CD) and
ulcerative colitis (UC) in comparison to healthy, non-smoking
volunteers. *Po 0.05 compared to controls, **Po 0.01 com-
pared to controls.
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FIG. 2. The correlation between eNO (ppb) and the disease
activity in Crohn’s disease.There is a signi¢cant correlation be-
tween eNOlevels and the Crohn’s disease activityindex (CDAI)
(r¼ 0.39, Po 0.05).
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The characteristics of the patients and the volunteers
groups are summarized inTable 1. The mean age of the
24 patients with UC (9 men and 15 women) was
38.0714.7 years. Their mean CAI and eNO were
6.274.8 and 15.876.2, respectively. Six patients had a
proctosigmoiditis, three a left-sided colitis and15 had ex-
tensive disease.
In the CD group, consisting of 17 men and 14 women
with a mean age of 36.8712.9 years, the mean CDAI
was192.4794.3.Their mean eNO was 13.574.6 ppb. In
the control group (14 men, 13 women) the mean age
(33.7713.2 years) was not signi¢cantly di¡erent from
the IBD patients. The healthy volunteers had a mean
eNO level of10.272.5 ppb.
Exhaled NO levels in patients with IBD and healthy
volunteers are depicted in Fig.1.
Patients with UC and CD had signi¢cantly higher
mean eNO (Po 0.01ando 0.05, respectively) levels than
healthy controls.The values of eNO tended to be higher,
although not signi¢cantly, in patients with UC compared
to thosewith CD (P¼ 0.1201).
The correlation between eNO levels and disease ac-
tivity in patients with UC and CD is demonstrated in
Figs. 2 and 3, respectively. A signi¢cant positive correla-
tion was found between eNO levels and disease activity
in both groups of patients.However, the correlationwas
more signi¢cant in patients with UC than in those with
CD (UC: r¼ 0.63, Po 0.001vs CD: r¼ 0.39, Po 0.05).
The mean eNO level in patients with left-sided UC
was 13.674.6 ppb and in those with pan-colitis
16.877.6 ppb. Although the values tended to be higher
in more extensive disease, no signi¢cant di¡erence was
observed (P¼ 0.3226).
According to the criteria of disease activity, 24 pa-
tients had active CD (77%) and six had active UC (25%).
Ten patients with CD (32%) were smokers.Only one pa-
tientwithUC (4%) smoked and therefore nothing canbe
said about the e¡ect of smoking on the level of eNO in
UC.
In a subgroup of 17 patients with CD (15 had active
CD), spirometry was performed after the eNO mea-TABLE 1. Characteristics of patients with ulcerative colitis (U
mean7standard deviation (SD); for UC the colitis activity index
are shown
UC
Number 24
Genderm/f 9/15
Mean age (SD) 38.0 (14.7)
Smokers 1
Mean eNO (SD) 15.8 (6.2)
Mean activity index (SD) 6.2 (4.8)surement. A signi¢cant negative correlation was found
between the CDAI and the FEV1 and FVC in these pa-
tients (r¼  0.559, P¼ 0.02 and r¼  0.634, P¼ 0.006, re-
spectively) [Fig. 4(A) and (B)].C), Crohn’s disease (CD) and controls. Values are given as
(CAI) and for CD the Crohn’s disease activity index (CDAI)
CD Controls
31 27
17/14 14/13
36.8 (12.9) 33.7 (13.2)
10 0
13.5 (4.6) 10.2 (2.5)
192.4 (94.3) F
05
10
15
20
25
30
35
0 5 10 15 20
CAI
e
N
O
 (
p
p
b
)
FIG. 3. The correlation between eNO (ppb) and the disease
activity in UC.There is a signi¢cant correlation between eNO
levels and the colitis activityindex (CAI) (r¼ 0.63, Po 0.001).
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This study has, for the ¢rst time, demonstrated a dis-
ease-activity-related increase of eNO in patients with
IBD. For patients with UC the correlation coe⁄cient
was stronger than for patients with CD. In comparison
with a control population, a signi¢cantly higher eNO
was also found in both groups with IBD.
The IBD patients hadno signs or symptoms of another
disease and were not known to have concomitant pul-
monary disease, which could interfere with the eNO
measurements. In several studies the active role of NO
in the in£ammatoryprocess of IBD has been established.
Direct and indirect methods have been used to demon-
strate elevatedNO levels in colonic gas (2^4) andmuco-
sal tissue (16); however, up to now an increased eNO in
IBD patients has not yetbeen described. Since themeth-
odweused tomeasure eNOis according to ERS andATS
guidelines, it is assumed that the eNO re£ects the in-
£ammation of the airways.
Since NO is rapidly deactivated by oxygenated hemo-
globin to form nitrate, it is not possible that the in-0
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FIG. 4. The correlation between CDAI and spirometry in17 patie
CDAI and FEV1 (r¼ 0.559, P¼ 0.02) (A) andbetween CDAI and FVCcreased eNO comes from the in£amed gut and is
exhaled via the lungs after transit in the bloodstream
(17).
In various lung diseases such as asthma (10,18,19), re-
spiratory-tract infections (20), bronchiectasis (21), and
chronic rejection after lung transplantation (22), an
increased eNO has been demonstrated as a possible
marker of airways in£ammation. NO from in£amed
airways is produced in epithelial cells, macrophages,
monocytes and other in£ammatory cells (23) by activa-
tion of inducible, calcium-independent, nitric oxide
synthase (iNOS) by pro-in£ammatory cytokines. In nor-
mal physiological situations, NO is produced by activa-
tion of constitutive, calcium-dependent NOS in
endothelial and epithelial cells (cNOS) and neurons
(nNOS) (24).
Lung involvement in in£ammatorybowel disease as an
extra-intestinal manifestation has been well recognized
for many years. Although respiratory problems in IBD
are rare, clinical and subclinical involvement of the lungs
in IBD has been described in di¡erent studies. A variety
of respiratory changes have hitherto been described in
IBD including in£ammatory involvement of the bronchial
tree at various anatomic levels, several forms of intersti-
tial pneumonitis, necrobiotic parenchymal nodules and
serositis (25). In rare cases, sulfasalazine and 5-aminosa-
licylic acidmay also be a cause of interstitial pneumonitis.
Mahadeva et al. described clinical and radiological ab-
normalities in patientswith IBD (26) andCamus stressed
the importance of early detection of lung involvement in
these diseases (27). In a recent study, Tzanakis and co-
workers showed that there is a dysfunction of the small
airways despite normal pulmonary function tests (PFT)
in patients with IBD.They also observed a normalization
of the small airway dysfunction when the patients were
treated with steroids (6). Furthermore, they found a re-
duced di¡using capacity for CO in the patients with ac-
tive CU, which improved upon treatment. Eade et al.
also found a signi¢cantly reduced di¡using capacity for0
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nts with CD.There is a signi¢cant negative correlation between
(r¼ 0.634, P¼ 0.006) (B).
534 RESPIRATORYMEDICINECO (Tlco) (28), whereas, Parquis et al. (29) observed no
di¡erence between PFT in 10 patients with active and
quiescent CD, which is comparable to the results ofTza-
nakis et al. (6). They showed, on the other hand, an in-
crease of the functional residual capacity in the group
with active disease. In a series of 54 patients with IBD
without pulmonary complaints, restrictive and obstruc-
tive PFTwere found in about 50% (30). In another study
of 102 patients with IBD, 50% had decreased PFT, and
25% a decreased di¡using capacity for CO. No correla-
tion, however, was foundbetween activity of disease, lo-
calization, concurrent drug administration or the
presence or absence of circulating immune complexes
or auto-antibodies (31). In contrast, we found a clear
and signi¢cant negative correlation between the CDAI
and thepulmonary function (FEV1and FVC) in17patients
with CD, of whom15 had active disease according to an
arbitrary CDAI4 150.We have no explanation for this
di¡erence in results, but our ¢ndings may represent an-
other argument for extra-intestinal (pulmonary) involve-
ment during active CD.
Using bronchoalveolar lavage, a subclinical alveolitis
has been demonstrated in 50% of patients with CD
(32,33). In a prospective study, Adenis et al. (34) found
an increasedpulmonarypermeability in patientswith ac-
tive CD, although they were free of respiratory symp-
toms and had a normal chest radiograph. Fireman et al.
recently demonstrated an increase of lymphocytes in in-
duced sputum of CD patients, none of whom had pul-
monary complaints (35).
Thepresent study suggests a relationshipbetween the
in£ammation in the bowel (as assessed by a speci¢c dis-
ease activity index) and an increase in eNO. Pro-in£am-
matory cytokines and bacterial products are present in
increased amounts in in£amed or infected tissues and,
due to increased intestinal permeability in IBD, the re-
lease of these pro-in£ammatory cytokines into the sys-
temic circulation could be facilitated (36), which might
then induce the expression of iNOS in other organs such
as the lung, resulting in airways in£ammation and an in-
creased eNO.This is consistent with the ¢nding of an in-
crease in airway eosinophils and lymphocytes in patients
with CD (7,35).
It is not clear at the present time why the pulmonary
involvement in IBD is not clinically signi¢cant in most of
the patients. In a few case reports, patients with CD de-
veloped pulmonary problems after a total colectomy
wasperformed (37).This intriguing shift of the in£amma-
tory process from the bowel to the lung is often taken as
evidence of a causal link between the two processes
(38,39). For the moment, the impact of chronic airways
in£ammation in patients with IBD is still to be investi-
gated and further research will be needed to explain
the exact pathophysiologicalmechanisms.
In conclusion, we have demonstrated that eNO seems
to be a useful indicator for disease activity in patientswith IBD, especially in those with UC.The involvement
of in£ammation of the bronchial mucosa, which is sug-
gested by the increased eNO levels, indeed provides
further evidence that IBD is a systemic disease. Also,
the presence of a negative correlation between disease
activity and spirometry in patients with CD points to
pulmonary involvement.The exact signi¢cance of these
¢ndings, however, needs to be elucidated.
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